Vergelijking
Gonadorelin vs. Icatibant
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
33515-09-2
138614-30-9
Molecuulmassa
1182.29 g/mol
1304.52 g/mol
Halfwaardetijd
0.1 h
geen gegevens
Sequentie
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2geen gegevens
Werkingsmechanisme
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
Icatibant
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
Bewijsbasis
Hoogste bewijs
Humane studie
Humane RCT
Studies
4
1
waarvan bij mensen
4
1
Geregistreerde effecten
4
1
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
2
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Gonadorelin and Icatibant?
- Gonadorelin is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Gonadorelin or Icatibant?
- The highest available evidence level is "Humane studie" for Gonadorelin and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Gonadorelin and Icatibant in Germany and the United States?
- Duitsland: Gonadorelin — Op recept, Icatibant — Op recept. Verenigde Staten: Gonadorelin — Op recept, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.